HCW Biologics Inc Net Assets
HCW Biologics Inc net assets. Based on the latest financial reports, HCW Biologics Inc (HCWB) has net assets worth $7.43 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.77 Million) and total liabilities ($19.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HCWB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.43 Million |
| % of Total Assets | 27.75% |
| Annual Growth Rate | -17.85% |
| 5-Year Change | -94.6% |
| 10-Year Change | N/A |
| Growth Volatility | 138.0 |
Net Assets of HCW Biologics Inc (2019–2025)
Net assets of HCW Biologics Inc from 2019 to 2025. This chart illustrates how HCW Biologics Inc's net assets have evolved over time, based on quarterly financial data. See HCWB equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for HCW Biologics Inc (2019–2025)
The table below shows the annual net assets of HCW Biologics Inc from 2019 to 2025. For live market cap and overall valuation, see HCWB company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.76 Million | +140.84% |
| 2024-12-31 | $-6.77 Million | -150.29% |
| 2023-12-31 | $13.46 Million | -64.03% |
| 2022-12-31 | $37.43 Million | -26.89% |
| 2021-12-31 | $51.19 Million | +255.58% |
| 2020-12-31 | $14.40 Million | +59.97% |
| 2019-12-31 | $9.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HCW Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9883908000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
HCW Biologics Inc Net Assets Breakdown (December 2025)
HCW Biologics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $328.00 | 0.01% |
| Other Components | $111.28 Million | 4024.94% |
| Total Equity | $2.76 Million | 100.00% |
HCW Biologics Inc Competitors by Market Cap
The table below lists competitors of HCW Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
$2.11 Million |
|
Human Xtensions Ltd
TA:HUMX
|
$2.12 Million |
|
Literacy Capital PLC
LSE:BOOK
|
$2.13 Million |
|
Haoxi Health Technology Limited Class A Ordinary Shares
NASDAQ:HAO
|
$2.13 Million |
|
Celtic PLC
LSE:CCP
|
$2.11 Million |
|
Downing Renewables & Infrastructure Trust PLC
LSE:DORE
|
$2.11 Million |
|
Martello Technologies Group Inc
V:MTLO
|
$2.11 Million |
|
Sri Havisha Hospitality and Infrastructure Limited
NSE:HAVISHA
|
$2.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HCW Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,770,172 to 2,764,769, a change of 9,534,941.
- Net loss of 7,959,709 reduced equity.
- New share issuances of 8,034,017 increased equity.
- Other factors increased equity by 9,460,633.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.96 Million | -287.9% |
| Share Issuances | $8.03 Million | +290.59% |
| Other Changes | $9.46 Million | +342.19% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares HCW Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.78x to 0.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.47 | $1.15 | x |
| 2020-12-31 | $2.35 | $1.15 | x |
| 2021-12-31 | $1.43 | $1.15 | x |
| 2022-12-31 | $6.27 | $1.15 | x |
| 2023-12-31 | $2.25 | $1.15 | x |
| 2024-12-31 | $-1.05 | $1.15 | x |
| 2025-12-31 | $7.91 | $1.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HCW Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -287.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14677.14%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 8.87x
- Recent ROE (-287.90%) is below the historical average (-94.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -81.03% | 0.00% | 0.00x | 1.12x | $-8.19 Million |
| 2020 | -40.15% | -140.98% | 0.27x | 1.07x | $-7.22 Million |
| 2021 | -25.13% | -313.74% | 0.08x | 1.05x | $-17.98 Million |
| 2022 | -39.81% | -221.67% | 0.14x | 1.25x | $-18.64 Million |
| 2023 | -185.67% | -879.52% | 0.10x | 2.12x | $-26.34 Million |
| 2024 | 0.00% | -1169.70% | 0.08x | 0.00x | $-29.35 Million |
| 2025 | -287.90% | -14677.14% | 0.00x | 8.87x | $-8.24 Million |
Industry Comparison
This section compares HCW Biologics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HCW Biologics Inc (HCWB) | $7.43 Million | -81.03% | 2.60x | $2.11 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more